Use of sildenafil and other phosphodiesterase type 5 inhibitors among pregnant women in Scandinavia

Carolyn E. Cesta*, Silvia Segovia Chacón, Anders Engeland, Anne Broe, Per Damkier, Kari Furu, Helle Kieler, Pär Karlsson


Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

14 Downloads (Pure)


Introduction: For phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil, the only approved indication in women is for pulmonary arterial hypertension. These drugs are increasingly being proposed and tested for treatment of female infertility and complications in pregnancy. However, the extent of use of PDE5 inhibitors in the general pregnant population over the last decades is unknown. Therefore, we conducted a descriptive cohort study using data from the population health registers in the Scandinavian countries. Material and methods: By linking the Medical Birth Registers and the Prescribed Drug Registers in Denmark (1997–2017), Norway (2004–2017), and Sweden (2006–2016), women with filled prescriptions of PDE5 inhibitors in outpatient settings in the 90 days before the date of last menstrual period and/or during pregnancies were identified. With additional linkage to the National Patient Registers, information on maternal, pregnancy, and infant characteristics, co-morbidities, and co-medication was collected and described. Results: Among over 3 million singleton pregnancies, only 77 were pregnancies in women who had at least one filled prescription of a PDE5 inhibitor within the 90 days before the start of pregnancy to delivery. Prescription fills most often occurred before the last menstrual period and in the first trimester, with very few occurring later in pregnancy. Sildenafil was the most used PDE5 inhibitor. Among pregnant women using PDE5 inhibitors, 44% were 35 years of age or older, eight had a cardiovascular diagnosis, and three specifically had a diagnosis of pulmonary arterial hypertension. Among the infants born to mothers using PDE5 inhibitors, nine were born preterm, six were small-for-gestational age, five had an Apgar score at 5 minutes below 8, 18 were admitted to the Neonatal Intensive Care Unit, and eight had respiratory and cardiovascular conditions. Conclusions: Few women used PDE5 inhibitors in outpatient settings before or during pregnancy in the Scandinavian countries in the last decades. Only a small proportion had a diagnosis for pulmonary arterial hypertension, suggesting off-label use in the remaining users. Use was predominantly in mothers over age 35 years. The safety of fetal exposure to sildenafil and other PDE5 inhibitors in pregnancy has not been established. As maternal age continues to increase and additional uses of PDE5 inhibitors are investigated, the safety of these drugs in pregnancy should be thoroughly evaluated.

TidsskriftActa Obstetricia et Gynecologica Scandinavica
Udgave nummer11
Sider (fra-til)2111-2118
StatusUdgivet - nov. 2021

Bibliografisk note

Funding Information:
This study was partly funded by the authors’ affiliations and by NordForsk (Nordic Pregnancy Drug Safety Studies project No. 83539), by the Research Council of Norway (International Pregnancy Drug Safety Studies project No. 273366), and by the Research Council of Norway through its Centers of Excellence funding scheme (project No. 262700). Anne Broe was supported by the Novo Nordisk Foundation (grant No. NNF17OC0028866)

Publisher Copyright:
© 2021 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG)


Dyk ned i forskningsemnerne om 'Use of sildenafil and other phosphodiesterase type 5 inhibitors among pregnant women in Scandinavia'. Sammen danner de et unikt fingeraftryk.